Abstract:Tuberculosis (TB) is an ancient infectious disease. Before the availability of effective drug therapy, it had high morbidity and mortality. In the past 100 years, the discovery of revolutionary anti-TB drugs such as streptomycin, isoniazid, pyrazinamide, ethambutol and rifampicin, along with drug combination treatment, has greatly improved TB control globally. As anti-TB drugs were widely used, multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of emerged due to acquired genetic mutations, and this now presents a major problem for effective treatment. Genes associated with drug resistance have been identified, including mutations in isoniazid resistance, mutations in rifampin resistance, mutations in pyrazinamide resistance, and mutations in quinolone resistance. The major mechanisms of drug resistance include loss of enzyme activity in prodrug activation, drug target alteration, overexpression of drug target, and overexpression of the efflux pump. During the disease process, may reside in different microenvironments where it is expose to acidic pH, low oxygen, reactive oxygen species and anti-TB drugs, which can facilitate the development of non-replicating persisters and promote bacterial survival. The mechanisms of persister formation may include toxin-antitoxin (TA) modules, DNA protection and repair, protein degradation such as trans-translation, efflux, and altered metabolism. In recent years, the use of new anti-TB drugs, repurposed drugs, and their drug combinations has greatly improved treatment outcomes in patients with both drug-susceptible TB and MDR/XDR-TB. The importance of developing more effective drugs targeting persisters of is emphasized. In addition, host-directed therapeutics using both conventional drugs and herbal medicines for more effective TB treatment should also be explored. In this article, we review historical aspects of the research on anti-TB drugs and discuss the current understanding and treatments of drug resistant and persistent tuberculosis to inform future therapeutic development.

Post-translational modification and regulatory network of Mycobacterium tuberculosis antibiotic resistance

The role of Mfd in Mycobacterium tuberculosis physiology and underlying regulatory network

The past, present and future of tuberculosis treatment.

The pathogenic mechanism of Mycobacterium tuberculosis: implication for new drug development

Antimicrobial resistance and mechanisms of epigenetic regulation

Metabolic Versatility of Mycobacterium tuberculosis during Infection and Dormancy

The Role of Mycobacterium Tuberculosis Acetyltransferase and Protein Acetylation Modifications in Tuberculosis

The Structural and Molecular Mechanisms of Mycobacterium tuberculosis Translational Elongation Factor Proteins

Drug Resistance Tomycobacterium Tuberculosis: from the Traditional Chinese View to Modern Systems Biology

Regulation of Protein Post-Translational Modifications on Metabolism of Actinomycetes

Genome-wide DNA Methylation and Transcriptome Changes in Mycobacterium Tuberculosis with Rifampicin and Isoniazid Resistance.

The characterization of conserved binding motifs and potential target genes for M. tuberculosis MtrAB reveals a link between the two-component system and the drug resistance of M. smegmatis

Actionable mechanisms of drug tolerance and resistance in Mycobacterium tuberculosis

Genes and Regulatory Networks Involved in Persistence of Mycobacterium Tuberculosis

The role of transcriptional regulators in metal ion homeostasis of Mycobacterium tuberculosis

The role of non-coding RNA on macrophage modification in tuberculosis infection

Metabolic Rewiring of Mycobacterium tuberculosis upon Drug Treatment and Antibiotics Resistance

Protein post-translational modification in prokaryotes

The profile of genome-wide DNA methylation, transcriptome, and proteome in streptomycin-resistant Mycobacterium tuberculosis

Immune regulation and emerging roles of noncoding RNAs in Mycobacterium tuberculosis infection

Molecular mechanisms of resistance and treatment efficacy of clofazimine and bedaquiline against Mycobacterium tuberculosis